This Plain Language Summary of publication article (PLSP) from Future Oncology, the phase 2 DeLLphi-301 study evaluated the effectiveness and safety of tarlatamab in people with small cell lung cancer (SCLC) who had previously undergone at least two treatments. Tarlatamab is a novel medicine that targets the DLL3 protein on cancer cells, enabling the immune system’s T cells to attack the cancer. Participants received either 10 mg or 100 mg doses of tarlatamab via intravenous infusion every two weeks, starting with a small 1 mg dose to reduce the risk of cytokine release syndrome (CRS).

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer’ and was published in NEJM

Visit NEJM using the link to read the original article.